Author: admin

  • Israel postpones demolition of Palestinian children’s football pitch in Bethlehem

    Israel postpones demolition of Palestinian children’s football pitch in Bethlehem

    BBC News Three Palestinian boys around 10 years old, wearing red football kit, wait in line to take a penalty. They are standing on a green astro turf football pitch with a metal fence behind them. Behind that stands a tall concrete wallBBC News

    The Aida Youth Centre’s pitch sits next to the barrier separating the occupied West Bank from Israel

    Israel has postponed the demolition of a Palestinian children’s football club in the city of Bethlehem, in the occupied West Bank.

    It said…

    Continue Reading

  • Global Weather Pattern Links Floods, Droughts Across the Planet

    Global Weather Pattern Links Floods, Droughts Across the Planet

    Scientists tracking Earth’s water from space discovered that El Niño and La Niña are synchronizing floods and droughts across continents, according to a new study published in AGU Advances by the University of Texas at Austin.

    Over the…

    Continue Reading

  • How Syria's government has redrawn map with advances against the Kurds – Reuters

    1. How Syria’s government has redrawn map with advances against the Kurds  Reuters
    2. Syria fighting updates: Government, SDF agree to four-day ceasefire  Al Jazeera
    3. Damascus gives Kurds four days to accept integration  Dawn
    4. Syrian presidency: Agreement…

    Continue Reading

  • Study shows chiral phonons can drive orbital currents

    Study shows chiral phonons can drive orbital currents

    Electrons’ orbital angular momentum could help create energy-efficient, low-power magnetic devices. These orbital currents usually come from 3d transition-metal magnets. They are generated either by an applied electric field or by changes in…

    Continue Reading

  • HEDD Audio welcomes the TYPE 20 A-CORE, expanding its A-CORE analogue monitor series

    HEDD Audio welcomes the TYPE 20 A-CORE, expanding its A-CORE analogue monitor series

    On the hunt for a latency and DSP-free monitor? Well, HEDD Audio has unveiled the latest addition to its analogue A-CORE Series, and its designed specifically for professional studio environments and any cases when clarity is absolutely…

    Continue Reading

  • BBC announces landmark deal to make bespoke content for YouTube | BBC

    BBC announces landmark deal to make bespoke content for YouTube | BBC

    The BBC has announced that it will produce tailor-made content for YouTube in a milestone for British television as the public service broadcaster teams up with the world’s biggest video platform.

    The corporation has previously posted clips and…

    Continue Reading

  • Shoulder Joint Range of Motion Falls After Breast Cancer Surgery – European Medical Journal Shoulder Joint Range of Motion After Breast Surgery

    Shoulder Joint Range of Motion Falls After Breast Cancer Surgery – European Medical Journal Shoulder Joint Range of Motion After Breast Surgery

    SHOULDER joint range of motion fell markedly 1 month after breast cancer surgery in Japan despite routine inpatient rehabilitation.

    Shoulder Joint Range of Motion Limits Common at 1 Month

    Early reductions in shoulder joint range of motion can…

    Continue Reading

  • Boehringer Ingelheim Launches Phase 2 Trial of IL-11 Antibody for IPF Treatment

    Boehringer Ingelheim Launches Phase 2 Trial of IL-11 Antibody for IPF Treatment

    A new clinical trial (NCT07036523) evaluating a novel monoclonal antibody to treat patients with idiopathic pulmonary fibrosis (IPF), conducted by Boehringer-Ingelheim, a biopharmaceutical company and investor in research and development, began recruiting participants in Germany.1,2

    The drug BI 765423 signifies another step forward in Boehringer-Ingelheim’s goal to advance innovative care for those living with IPF.1 Despite numerous standard therapies that may help slow the progression of the disease, there still remains an unmet need to stop disease progression and reverse lung tissue damage completely. Prior research and ongoing clinical trials suggest a potential breakthrough in stopping the progression of the disease with experimental, targeted, oral therapies.3 BI 765423 targets pleiotropic cytokine IL-11 inhibition—a key biomarker and mediator of fibrosis.1

    “With BI 765423, we aim to go beyond slowing disease and to pursue next-generation therapies that could restore lung functionality for people living with IPF,” Vittoria Zinzalla, global head of Experimental Medicine at Boehringer Ingelheim, said in a press release.

    BI 765423 is designed to bind directly to IL-11, thus interrupting the signaling pathways that cause fibrosis. Prior preclinical studies have shown that inhibiting IL-11 can halt fibrosis and restore barrier function.1 Another phase 2a clinical trial demonstrated reduced type 2 (IL-4 and IL-13) and type 3-associated cytokines (IL-17a and IL-22) when targeting invariant natural killer T cells (iNKT) in patients with IPF. Thus, supporting Boehringer-Ingelheim’s objective to target profibrotic cytokines, which may reduce fibrosis and lung tissue damage in patients with IPF while restoring lung functionality.

    In phase 1 of the biopharmaceutical company’s clinical trial, BI 765432 demonstrated favorable safety and tolerability in participants. Phase 2 of the clinical trial aims to evaluate the efficacy of the drug.

    The double-blind, randomized, placebo-controlled, parallel-group study is open to adults with IPF aged 40 or older of either sex. Participants must have a forced vital capacity greater than or equal to 45% and fibrosis of 20% or more confirmed by a high-resolution computed tomography. Patients must also have a hemoglobin-corrected diffusing capacity of the lungs for carbon monoxide (DLCO) of 20% or greater.

    Participants will be randomized 1:1 to receive BI-765432 or a placebo, administered intravenously every 4 weeks for 8-10 months. During the study, participants can continue their regular treatment for IPF and frequently visit the study site for screenings, treatment, and follow-up.2

    Some of the outcomes expected to be measured include absolute change in FVC, DLCO, oxygen saturation, distance walked during a 6-minute walk test, and log10-transformed SPD plasma concentration from baseline to 12 weeks.

    There are currently 71 participants enrolled in the clinical trial. The study is expected to be completed in September 2027. Of the 50 study locations, 6 sites have begun recruiting participants: Chesterfield, Missouri; Franklin, Tennessee; Chermside, Queensland, Australia; Hanover, Germany; Fukuim Yoshida-gun, Japan; and Busan, South Korea.

    Although Boehringer Ingelheim is evaluating the safety and efficacy of BI 765423, the company acquired the drug from Enleofen to continue its development and maintain control. The drug’s intellectual property—including patents, data, and know-how—was in-licensed by Enleofen from Singapore Health Services and the National University of Singapore.1

    “Our aim is to transform the lives of patients and their families by demonstrating the potential of this first-in-class IL-11 inhibitor to deliver clear benefits for patients, backed by compelling evidence and delivered at speed,” Zinzalla said.

    References:

    1. Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to phase II clinical research in idiopathic pulmonary fibrosis. News release. Boehringer-Ingelheim. January 13, 2026. Accessed January 20, 2026. https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/new-trial-explores-advancements-ipf-treatment

    2. A study to find out whether BI 765423 has an effect on lung function in people with idiopathic pulmonary fibrosis (IPF) with or without standard treatment. Clinicaltrials.gov. January 6, 2026. Accessed January 20, 2026. https://clinicaltrials.gov/study/NCT07036523?a=11#contacts-and-locations

    3. McCrear S. Phase 2a trial shows Gri-0621 improves biomarkers and lung repair in IPF. AJMC. January 20, 2026. Accessed January 20, 2026. https://www.ajmc.com/view/phase-2a-trial-shows-gri-0621-improves-biomarkers-and-lung-repair-in-ipf

    4. Gri Bio announces additional positive data from phase 2A study in idiopathic pulmonary fibrosis, strengthening clinical proof-of-concept for GRI-0621. News release. GRIbio. January 8, 2026. Accessed January 20, 2026. https://gribio.com/gri-bio-announces-additional-positive-data-from-phase-2a-study-in-idiopathic-pulmonary-fibrosis-strengthening-clinical-proof-of-concept-for-gri-0621

    Continue Reading

  • Iran deaths went beyond protesters, hitting bystanders too, witnesses say – Reuters

    1. Iran deaths went beyond protesters, hitting bystanders too, witnesses say  Reuters
    2. End Protest Massacres in Iran  Amnesty International
    3. Iran ‘just getting started’ on punishing ‘rioters’ arrested during protests  Al Jazeera
    4. Govt admits…

    Continue Reading

  • Trump says US will not use force to acquire Greenland – Business Recorder

    1. Trump says US will not use force to acquire Greenland  Business Recorder
    2. Trump drops tariffs threat over Greenland after Nato talks  BBC
    3. Trump updates: US president says ‘framework’ reached for Greenland deal  Al Jazeera
    4. Five takeaways from…

    Continue Reading